RadNet, Inc. (RDNT) SEC filings

RDNTNasdaqServices-Medical LaboratoriesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3055% above fair value

$76.04−2.04 (-2.61%)

Close on Nov 12, 2026Market cap $5.98BP/E –Yield –

SEC filings

40 of RadNet's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 8, 2026	Nov 9, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2026	Nov 9, 2026	SEC EDGAR
Current report	8-K	Oct 26, 2026	Oct 26, 2026	SEC EDGAR
Current report	8-K	Aug 14, 2026	Aug 14, 2026	SEC EDGAR
Current report	8-K	Aug 9, 2026	Aug 10, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 10, 2026	SEC EDGAR
Current report	8-K	Jun 10, 2026	Jun 10, 2026	SEC EDGAR
Current report	8-K	Jun 3, 2026	Jun 4, 2026	SEC EDGAR
Current report	8-K	Jun 3, 2026	Jun 3, 2026	SEC EDGAR
Current report	8-K	May 10, 2026	May 11, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 11, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 2, 2026	Apr 20, 2026	SEC EDGAR
Current report	8-K	Mar 2, 2026	Mar 2, 2026	SEC EDGAR
Current report	8-K	Mar 2, 2026	Mar 2, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 2, 2026	SEC EDGAR
Current report	8-K	Jan 30, 2026	Jan 30, 2026	SEC EDGAR
Current report	8-K	Jan 6, 2026	Jan 9, 2026	SEC EDGAR
Current report	8-K	Dec 4, 2025	Dec 4, 2025	SEC EDGAR
Current report	8-K	Nov 9, 2025	Nov 10, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 10, 2025	SEC EDGAR
Current report	8-K	Oct 21, 2025	Oct 21, 2025	SEC EDGAR
Current report	8-K	Aug 10, 2025	Aug 11, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 11, 2025	SEC EDGAR
Current report	8-K	Jul 17, 2025	Jul 17, 2025	SEC EDGAR
Current report	8-K	Jun 10, 2025	Jun 12, 2025	SEC EDGAR
Current report	8-K	May 11, 2025	May 12, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 12, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 10, 2025	Apr 28, 2025	SEC EDGAR
Annual report, amended	10-K/A	Dec 31, 2024	Apr 28, 2025	SEC EDGAR
Current report	8-K	Apr 15, 2025	Apr 15, 2025	SEC EDGAR
Current report	8-K	Feb 27, 2025	Mar 5, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 3, 2025	SEC EDGAR
Current report	8-K	Nov 26, 2024	Nov 26, 2024	SEC EDGAR
Current report	8-K	Nov 10, 2024	Nov 12, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 12, 2024	SEC EDGAR
Current report	8-K	Oct 10, 2024	Oct 11, 2024	SEC EDGAR
Current report	8-K	Sep 11, 2024	Sep 12, 2024	SEC EDGAR
Current report	8-K	Aug 7, 2024	Aug 9, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 9, 2024	SEC EDGAR
Current report	8-K	Jun 12, 2024	Jun 13, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in RadNet's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-2 reverse split on Nov 28, 2006
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is RDNT.

Compare: RDNT vs DGX · RDNT vs NTRA · RDNT vs FLGT · RDNT vs FTRE · RDNT vs GH

Revenue growth21.1% · median 9.1%

Operating margin3.1% · median -9.0%

Net margin-0.9% · median -5.7%

Company	Revenue	Growth
DGX	$11.84B	+9.1%
NTRA	$2.91B	+37.4%
FTRE	$2.67B	-3.4%
RDNT	$2.38B	+21.1%
GH	$1.28B	+41.7%
FLGT	$330.28M	+4.7%

Company

Next earnings (est.): Mar 1, 2027, before open
Exchange: Nasdaq
Industry: Services-Medical Laboratories
Fiscal year ends: December 31
Employees: 76
Held by institutions: 100.0%
Auditor: Ernst & Young LLP
SEC CIK: 790526

Advertisement
300 × 250

See a number that looks wrong?